G astric adenocarcinoma (herein referred to as gastric cancer [GC] ) is the leading cause of cancer-related death worldwide. Despite progress in Helicobacter pylori eradication and early cancer screening, the 5-year survival rate for GC remains 29.6% worldwide. 1 Gastric cancer is genomically heterogeneous, with varying tumor mutation loads (TMLs). Recent studies have shown that GC samples with microsatellite instability-high (MSI-H) or POLE (OMIM 174762) mutations had DNA mismatch repair (MMR) signatures and higher TMLs.
2,3 Tumor mutation load is an important determinant in molecular subtyping of GC in The Cancer Genome Atlas (TCGA). With the use of GC samples in TCGA, 4 molecular subtypes have been identified, each defined by distinct genomic characteristics. 3 Previous studies of GC showed that clonal complexity and driver mutation patterns were associated with survival. 2, 4 Recent advances in immunotherapy
show that MMR-deficient tumors are more sensitive to immune checkpoint blockade, irrespective of tissue of origin.
5
MUC16 is a type I transmembrane mucin protein with 3 components: a C-terminal domain, a tandem repeat region, and an extracellular N-terminal section. 6, 7 Cancer antigen 125 (CA-125), used to monitor disease progression in ovarian cancer, is part of the tandem repeat domain.
7
MUC16 (OMIM 606154) is one of the most frequently mutated genes in GC; however, its associations with TML and prognosis remainunclear.Inthisstudy,weinvestigatedwhetherMUC16muta-tions are associated with TML and prognosis in patients with GC.
Methods

Genomic Data of GC
Somatic mutation and gene expression data for 437 GC samples in the TCGA were downloaded from Genome Data Commons (https://portal.gdc.cancer.gov). For the Asian cohort, clinical and somatic mutation data were obtained from a previous study. 2 The Asian cohort contained data from 256 patients with GC, comprising 78 patients from northern China (1 sample from this group had no mutation in its exomic region and was excluded), 4 100 from Hong Kong, 8 49 from South Korea, 9 and 30 from Japan. 10 Gene expression data for the Asian cohort are not available, and survival data were only available for the 78 patients from northern China. We did not include esophageal adenocarcinoma in our study because it differs substantially from GC with respect to mutational signatures, driver mutations (eg, 
Mutational Signature Extraction
We used SignatureAnalyzer 11 (https://software.broadinstitute .org/cancer/cga/Home) to extract mutational signatures by combining somatic mutation data from the TCGA and Asian cohorts rather than by extracting signatures in each cohort separately. SignatureAnalyzer uses Bayesian-based nonnegative matrix factorization that automatically determines the optimal number of mutational signatures. The Bayesian nonnegative matrix factorization method exploits a shrinkage or automatic relevance determination technique by iteratively pruning components that do not contribute to explanation of final mutation portraits. SignatureAnalyzer factorized the mutational portrait matrix A into 2 nonnegative matrices, W and H (ie, A equals approximately W × H), with W representing mutational signatures and H representing mutational activities. The number of columns of matrix W is the number of mutational signatures. The rows of matrix A are the 96 mutational contexts, and its columns are the 693 GC samples of both cohorts. The 96 mutational contexts are derived from combinations of 6 mutational types (ie, C > A, C > G, C > T, T > A, T > C, and T > G) and their 5′ and 3′ adjacent bases. The pruning process is performed by introducing weight parameter λ k , which is associated with the kth column of W and the kth row of H. During inference, the columns and rows of irrelevant components rapidly shrink to zero as λ k approaches the optimal number of signatures, which is the number of nonzero columns of matrix W. 
MUC16 Mutations vs TML
Because mutations in BRCA1/2 (OMIM 113705 and OMIM 600185, respectively) and POLE and MMR deficiency increase mutation rates in the cancer genome, 3 we used a multivariate regression model to analyze associations between MUC16 mutation and TML by including them as confounding factors. Tumor mutation load is defined as log 2 transformation of mutation rate per megabase. The extracted MMR mutational signatures were treated as binary variables (ie, 0 and 1) in the multivariate model according to the principle used in a previous study: a signature was considered significant if it contributed to more than 100 substitutions or more than 25% of total mutations. 13 We used stan_lm from the R package rstanarm, version 2.13.1 (https://cran.r-project.org/web/packages/rstanarm /index.html) to perform multivariate regression analyses.
Significantly Mutated Genes
We used the MutSigCV algorithm 14 to define significantly mutated genes (SMGs) in GC samples with and without MUC16 mutations. Before performing MutSigCV analysis, we removed GC samples with substantial MMR signatures (>100 substitutions or >25% of total mutations) to avoid skewing the results. An additional procedure was performed to identify expressed SMGs in TCGA data 15 and an encyclopedia of cell lines
16
; a gene was considered to be expressed if it had 3 or more reads in 75% or more of the samples, as described in a 2013 study by Kandoth et al. 15 
Gene Set Enrichment Analysis
As in the analysis of SMGs, we first removed samples with significant MMR signatures and mutations in BRCA1/2 and POLE. The R packages limma 17 and edgeR 18 were used to evaluate differential expression of each gene in GC samples with and without MUC16 mutations. Specifically, read counts of gene expression data were downloaded from Genomic Data Commons (https: //gdc.cancer.gov) and normalized by calcNormFactors in R package edgeR, and then fed to lmFit and eBayes functions in the R limma package. The differential expression statistics obtained from the eBayes function were used as input to perform gene set enrichment analysis for a list of cell-signaling pathways downloaded from MSigDB. 19 The fast gene set enrichment analysis algorithm 20 implemented in the Bioconductor R package fgsea was used. The P value was calculated based on 1 million permutations.
Prognosis
Kaplan-Meier survival and multivariate Cox regression analyses implemented in the R package survival were used to analyze associations between MUC16 mutations and survival. The log-rank test was used to determine significant differences of survival curves stratified by MUC16 mutations. A 2-sided P < .05 was considered statistically significant. Median overall survival time and 95% CIs are reported where relevant.
Results
TCGA Cohort
Of the 437 patients in the TCGA cohort, 280 (64.1%) were male, and the median (IQR) age was 67.6 (15.3) years. MUC16 was one of the most frequently mutated genes in the TCGA cohort, Figure 1A ). Of the GC samples with MUC16 mutations, 73 of 165 (44.2%) also harbored mutations in genes related to maintenance of genomic integrity, DNA replication proofreading, and MMR, such as BRCA1/2, POLE,andMLH3 ( Figure 1B ). The mutational associations between MUC16 and its family members are shown in Figure 1B .
MUC16 Mutation Association With TML
Gastric cancer samples with MUC16 mutations had a significantly higher mutation rate ( Figure 2A ; Wilcoxon rank sum test, P < .001). Tumor mutation load is largely attributed to genomic instability, which is prevalent in GC. In these samples, we found 6 mutational signatures (eFigure 1 in Supplement 1), including those related to genomic instability. To rule out the possibility that associations between MUC16 mutations and TML were affected by these confounding factors, we included all mutational signatures (except signature 10) and mutations in BRCA1/2 and POLE in the multivariate model. Four GC samples showed a significant presence of signature 10 and 2 samples harbored somatic mutations in POLE. Associations between MUC16 mutations and TML remained statistically significant (OR, 1.87; 95% CI, 1.49-2.36; Wilcoxon rank sum test, P < .001) ( Figure 3A ).
Survival in TCGA Cohort
In Kaplan-Meier survival analysis, the MUC16 mutation was significantly associated with a better survival outcome in the TCGA cohort ( Figure 2B ; median overall survival, 46.9 [95% CI, 26.4-NA (not available)] vs 26.7 [95% CI, 20.2-43.1] months; log-rank test, P = .007). This association remained statistically significant after controlling for confounding factors such as age, sex, TNM stage, mutations in BRCA1/2 and POLE, and defective MMR signatures (hazard ratio, 0.61 [95% CI, 0.42-0.89]; log-rank test, P = .01) ( Figure 3B ).
Independent Validation of MUC16 Mutations in the Asian Cohort
Of the 256 patients in the Asian cohort, 141 (55.1%) were male and median (IQR) age was 63 (17.8) years. MUC16 was also frequently mutated (57 of 256 patients [22.3%]) in the Asian cohort, as were BRCA1/2, POLE, and MLH3 (26 of 256 patients [10.2%] total for all 3). A significantly higher mutation count was also observed in GC samples with MUC16 mutations (mutation count, 134 vs 74; Wilcoxon rank sum test, P < .001) (eFigure 6A in Supplement 1; upper panel). The most prevalent mutational signatures included signature 1, which accounted for 11 401 of 30 115 total mutations (37.9%), and signature 2, which accounted for 7628 of 30 115 (25.3%). Mismatch repair signature 15 contributed to 4363 of 30 115) total mutations (14.5%) and MMR signature 21 contributed to 2158 of 30 115 (7.2%) (eFigure 6B and C in Supplement 1). Associations of mutations among the mucin gene family and 
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BRCA1/2, POLE, and MLH3 are shown in the middle panel of eFigure6AinSupplement 1. As in TCGA cohort, GC samples with MUC16 mutations had significantly more mutations than those without MUC16 mutation (TML, 2.1 vs 1.2 per megabase; log 2 transformation of mutation count per megabase; Wilcoxon rank sum test, P < .001) ( Figure 4A ). The association of MUC16 mutations with higher TML remained statistically significant after controlling for age, sex, TNM stage, mutational signatures, and mutations in BRCA1/2 and POLE in the multivariate model (OR, 1.69; 95% CI, 1.25-2.29; P < .001) ( Figure 5A ). In Kaplan-Meier survival analyses, MUC16 mutations were significantly associated with better survival outcomes ( Figure 4B ; median overall survival, not calculable [the median overall survival of patients with GC and MUC16 mutations could not be calculated because more than half the patients in the group were alive] vs 36.8 months; log-rank test, P = .04). This association remained statistically significant after controlling for confounding factors such as age, sex, TNM stage, and mutational signatures (hazard ratio, 0.26 [95% CI, 0.07-1.02]; P = .05) ( Figure 5B ).
Significantly Mutated Genes and Pathways Associated With MUC16 Mutations
In this analysis, we excluded GC samples with significant MMR signatures and mutations in BRCA1/2 and POLE (see Methods). We performed SMG and gene set enrichment analyses for GC samples with and without MUC16 mutations, respectively. The SMG mutational landscapes of these 2 groups (eFigure 7 in Supplement 1) exhibited differential mutations in RPL22 previously its mutation was associated with resistance to immune checkpoint blockade in melanoma. 22 Signaling pathways involved in the immune system, cell cycle checkpoints, antigen processing, and DNA replication and repair were 
Discussion
We analyzed 437 GC samples from the TCGA cohort and 256 GC samples from an Asian cohort for validation. MUC16 was frequently mutated in GC, and its mutation was associated with higher TML and better survival outcome. The association of MUC16 mutation with TML was independent of a significant presence of mutational signatures and of mutations in BRCA1/2 and POLE. Gastric cancer samples with MUC16 mutations were characterized by upregulation of signaling pathways involved in immune response, antigen processing, cell cycle checkpoints, and DNA replication and repair. MUC16 is frequently mutated in multiple types of human cancer. Owing to its large size, it was often excluded from lists of significantly mutated genes.
14 Nonetheless, MUC16 is known to modulate immune response to cancer. 6 Our gene set enrichment analyses also indicated that immune response, cell cycle checkpoints, and DNA replication and repair were significantly altered in GC samples with MUC16 mutations. Therefore, therapeutic regimens to abrogate immune inhibition, such as immune checkpoint blockade, may be beneficial for patients with GC who have MUC16 mutations. Gastric cancer may develop other strategies to survive host immune attack, such as loss of antigen presentation via B2M mutation (eFigure 7 in Supplement 1), which has been associated with acquired resistance to anti-programmed death 1 immunotherapy in patients with melanoma.
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Limitations
Our study has several limitations. First, somatic mutation data of the Asian cohort were aggregated from 4 previous studies, 4,8-10 and the tools used in analyzing sequencing data may have been different between these studies. This difference in sequencing could introduce bias in the final mutation list. Second, the number of samples with follow-up data in the Asian cohort was limited, which limits the ability to adjust for confounding factors. In the Asian cohort, TML was significantly lower in the TCGA cohort (1.4 vs 2.2 log 2 transformation of mutation count per megabase; Wilcoxon rank sum test, P < .001). 
Conclusions
In 2 independent genomic data sets from TCGA and Asian cohorts, MUC16 mutations were associated with higher TML and improved outcome in patients with GC. This finding may have implications for prognostic prediction and therapeutic guidance for GC. Invited Commentary Gastric cancer is a global health problem; although incidence rates are declining, it remains the third most common cause of cancer death worldwide. Patients with advanced disease have limited treatment options, and most will live for less than 2 years. Therefore, exploration of gastric cancer disease biology is warranted to identify new targets for treatment. Recent comprehensive molecular analyses have identified distinct subgroups of gastric cancer that may have therapeutic relevance. With the exception of microsatellite-unstable tumors, however, the potential for genomically guided therapy has not been realized.
MUC16 Mutations and Prognosis in Gastric Cancer
In this issue of JAMA Oncology, Li and colleagues 1 investigate the association between MUC16 (OMIM 606154) mutation, tumor mutation load (TML), and survival in patients with gastric adenocarcinoma. Using data from The Cancer Genome Atlas (TCGA) gastric cancer data set and a second, smaller Asian validation cohort, the investigators show that tumors with MUC16 mutations are more likely to have a significantly higher TML than those without. This association was independent of age, sex, and the presence of mutations in genes affecting genomic stability, such as BRCA1/2 (OMIM 113705 and OMIM 600185, respectively) and POLE (OMIM 174762). Independence from microsatellite instability (MSI) status could not be determined because MSI results were not available for every patient in the TCGA cohort; however, the association between MUC16 mutation and TML also appeared to be independent of derived mismatch repair deficiency signatures. Li and colleagues proceed to show that patients who have MUC16-mutant tumors have longer median overall survival than patients with an MUC16 wild-type tumor genotype. In patients in the TCGA cohort with resected gastric cancer, the median overall survival was 26.7 months for MUC16 wild-type vs 46.9 months for MUC16-mutant tumors (P = .007); similar results were evident in the Asian data set. The prognostic association of the MUC16 mutation with overall survival remained statistically significant when adjusted for confounding factors. The findings presented by Li et al are interesting; if MUC16 mutation is truly predictive of high TML, this finding could have clinical implications. The most obvious use of MUC16 mutation as a surrogate for TML in gastric cancer would be to identify 
